Company PresentationSeptember 2020

This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federalsecurities laws. For example, we are using forward-looking statements when we discuss the expected timing of obtaining regulatory approval for our variouspatient trials and clinical data readout, proposed trials that may occur in the future, the timing and implementation of our collaborations with various partnersand the execution of definitive agreements relating to such collaborations and the potential benefits and impact our products could have on improving patienthealth care. These forward-looking statements and their implications are based on the current expectations of our management only, and are subject to anumber of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The followingfactors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and marketrequirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved byregulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may beunable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop withour process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinicalsettings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harmrecipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure onpricing resulting from competition, which could cause our actual results or performance to differ materially from those contemplated in such forward-lookingstatements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflectevents or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertaintiesaffecting us, reference is made to our reports filed from time to time with the Securities and Exchange Commission

Forward Looking Statement

2

3

• Cell therapy company focused on Regenerative Medicine

• Several Off-the-shelf placenta-derived cell product candidates

• Two ongoing Phase III studies in critical limb ischemia (CLI)

associated with diabetes complications and in muscle regeneration

• Playing active role in clinical development for complications

associated with COVID-19

• Favorable safety profile and efficacy data from hundreds of

patients treated worldwide

• Best-in-class cell manufacturing technology producing

highest-quality cell products at a commercial scale

• Strong IP portfolio (over 120 granted patents)

• Publicly-listed on Nasdaq and TASE

• Cash: ~$59 million (as of June 30, 2020)

• Full time employees: ~150

Pluristem Therapeutics

The Need for Cell Therapy

Complexity of the diseaseInnovative treatments are needed to treat complex diseases

The Economic ImpactSome of the world’s largest economies are now facingsubsequent increases in health-care costs.

The Human ImpactAging is often associated with debilitating medical conditions,many of which are still unmet needs.

Longer lifespansLifespan has increased significantly.Nearly 2 billion people across the world are expected to be over 60 years old by 2050 (World Health Organization).

4

5

Placenta-Derived Cells

• Ethically accepted

• Rich & diverse

• Pro-angiogenic & immunoregulatory

• Young donors after full-term delivery, undergoing an elective caesarean section

• Unlimited source & easy to collect

• Ability to manufacture treatments for over 20,000 patients per placenta

The Placenta Project was

launched by the US National

Institutes of Health (NIH) in 2013

to further explore the role of the

placenta in health and disease

http://www.the-scientist.com/?articles.view/articleNo/43618/title/The-Prescient-Placenta/

Market-ready Industrialized Technology Platform

Manufacturing Process Approved by:6

State-of-the-art, proprietary bioreactor systemwhich provides a 3D micro-environment for cellsthat mimics the human body condition

Controlled, automated, efficient and scalablemanufacturing technology

Market-ready, cost effective industrialized platform

Controlling the conditions within our bioreactorsallows us to produce several unique patentedproducts

Pluristem in One Slide

Simple IM administration

Adaptive slow secretion of

cytokines

Long-term regenerative

effect

Placenta Technology-Strong IP portfolio

Allogeneic Off-the-shelf

Several product candidates

7

IndicationProduct

CandidateLocation Pre-Clinical Phase I Phase II

Phase III

Funding

Clinical Pipeline

via FDA Animal Rule

Critical Limb Ischemia

Intermittent Claudication

Muscle Regeneration following Hip Fracture

Acute Radiation Syndrome*

PLX-PAD

PLX-PAD

PLX-PAD

PLX-R18

Graft Versus Host Disease PLX-PAD

Incomplete Recovery following Bone Marrow Transplantation PLX-R18

U.S., Europe Israel

U.S., Europe South Korea,

Israel

U.S., Europe Israel

U.S.

Israel

U.S., Israel

* FDA Orphan Drug Designation

ARDS due to COVID-19 PLX-PADU.S.

Germany

PLX-PAD

Peripheral Arterial Disease

9

• CLI is caused by fatty deposits in leg arteries that obstruct blood flow

• Risk factors include smoking, diabetes, obesity, cardiovascular problems and hypertension

• CLI patients suffer from severe pain, skin wounds, tissue necrosis and poor quality of life

• High risk of leg amputation and death

• Up to 35% of patients are unsuitable or will not benefit from revascularization

Peripheral Arterial Disease – Critical Limb Ischemia (CLI)

10

PLX-PAD is designed to treat CLI by reducing inflammation and stimulate the growth of blood vessels to bring oxygenated blood to ischemic tissue

5 Year Mortality Rate Inpatient & Outpatient Treatment Costs by Rutherford Category

Clinical Development in Peripheral Arterial Disease

11

Completed two Phase I studies in CLI – U.S. & Germany (N=27)

Good safety profile

Increase in tissue perfusion, 60% reduction in the risk for death or amputation

Dose identification – two treatments of 300 million cells, two months apart

Completed Phase II study in intermittent claudication (IC) – U.S., Germany, S. Korea & Israel

Good safety profile

Significant increase in walking distance, reduction in surgical events and HbA1c and CRP levels

Confirmation of Phase III design including – dose (300m cells), dose regimen (2 administrations)

(N=172)

12

Ongoing Phase III study in CLI – U.S., Europe & Israel

Ongoing CLI Phase III Study

• Expected top-line interim data analysis results in Q4/2020 (calendar year)

• Patient enrollment to the full clinical study ongoing

• Awarded adaptive pathway program in the EU

Disclaimer: The results presented above are a small sample of the ongoing trial, chosen by the principal investigator, and are not representative of the full trial population. These results may not be typical and could be materially different from the results reported at the completion of the trial. Investors are cautioned to consider this sample data at their own risk.

€ 7.6 million grant from the EU Horizon 2020 program

Design Phase III, randomized, Double-Blind, Placebo-controlled (2:1)

Study population CLI subjects with minor tissue loss, unsuitable for revascularization

Countries Germany, UK, U.S., Poland, Hungary, Czech Republic, Bulgaria, Macedonia, Israel

Sample size Randomization will stop when required amount of events (82) is assured

Doses tested 300M cells vs. placebo (randomization ratio 2:1)

Administration IM injections in the affected leg, 2 treatments at 8-week interval

Primary efficacy endpoint Time to occurrence of major amputation of leg or death (AFS)

Main secondary & exploratory efficacy endpoints

Composite efficacy endpoint; Pain; Complete wound healing; Quality-of-life; Adjudicated amputations; TcPO2; Cytokine levels

Follow-up length 52 weeks

Expected top-line interim data analysis results

Q4 calendar year of 2020

13

Ongoing CLI Phase III Study - Overview

PLX-PAD

Muscle Regeneration

14

PLX-PAD is designed to stimulate muscle regeneration –gain muscle strength and volume

15

There are currently no approved treatments for post-operative regeneration of injured or weak skeletal muscle

Muscle Regeneration Following Hip Fracture

• As the population ages, the number of hip fractures continuesto increase

• Worldwide, the total number of hip fractures is expected tosurpass 6 million by the year 2050*

• Hip fracture often leads to serious long-term complications,including pain, functional decline and disability**

• Up to 36% mortality rate after one year due to immobilityassociated diseases***

*Kannus P, Parkkari J, Sievänen H, et al. Epidemiology of hip fractures**Simran Mundi, et. al. 2014***Jorma Panula, et. al. 2011

Contralateral(non–operated)

16

Phase I/II Study of PLX-PAD for Muscle Injury Following Total Hip Replacement (N=20)

Change in Volume Improvement of 300%

P=0.004

Change in Strength Improvement of 500%

P=0.0067

Change in Strength Improvement of 4000%

P=0.012

• PLX-PAD demonstrated a significant increase in muscle strength & volume compared to placebo

• First study to show efficacy of cell therapy in skeletal muscle injury

Muscle Regeneration

Ongoing Muscle Regeneration Phase III Study

Design Phase III, randomized, Double-Blind, Placebo-controlled

Study population Patients suffering from muscle injury following arthroplasty for hip fracture

Countries U.S., Germany, UK, Denmark, Israel

Sample size 240 patients

Doses tested 150M cells vs. placebo (randomization ratio 1:1)

Administration IM injections in the operated leg on the day of surgery

Primary efficacy endpoint Short Physical Performance Battery (SPPB) score at week 26

Main secondary & exploratory efficacy endpoints

Muscle strength, muscle mass & volume, hospitalization time, lower extremity measure

Follow-up length 26 (efficacy), 52 weeks (safety)

Expected top-line results Q3 calendar year of 2021

17 € 7.4 million grant from the EU Horizon 2020 program

• More than 60% of the study’s population enrolled

PLX-PAD

Coronavirus – COVID-19

18

PLX-PAD has anti-inflammatory and immunomodulatory properties, potentially leading to reduction of inflammation and lung injury

19

• The 2019 novel coronavirus (SARS-CoV-2) infection causes clusters of severe respiratory illness associated witha need for intensive care unit (ICU) admission and high mortality. Studies have revealed that pneumonia is themost common complication, followed by Acute Respiratory Distress Syndrome (ARDS)*

• Cytokine storm (CS) refers to excessive and uncontrolled release of pro-inflammatory cytokines, commonlypresents as systemic inflammation, multiple organ failure, and high inflammatory parameters. In coronaviruspneumonia, the infiltration of a large number of inflammatory cells and a CS lead to acute lung injury, ARDSand death**

PLX Cells as Treatment for Severe COVID-19 Cases Complicated by Acute Respiratory Distress Syndrome (ARDS)

• PLX cells may potentially reduce the incidence and/or severity of COVID-19 pneumonialeading hopefully to a better prognosis for the patient

• Good safety profile of PLX-PAD has been observed from clinical trials involving hundreds ofpatients worldwide

• PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties thatinduce the immune system’s natural regulatory T cells and M2 macrophages, and thus mayprevent or reverse the dangerous overactivation of the immune system

Source: *Wang 2020, Guan 2020 ; **Channappanavar 2017, Zhang 2020

• Reported (May 14, 2020) in a 28-day follow up of 8 (1 in the U.S. and 7 in Israel) out of 18 ventilator-dependent COVID-19 patients treated under compassionate use programs in Israel and the U.S.: 87.5% survival rate 75% of patients were off any mechanical ventilation 62.5% of the patients were discharged alive from the hospital*

• Received FDA clearance for the Expanded Access Program in the U.S.

• Continues with Per Patient Compassionate Use Program in Israel

Phase II studies

• Expected end of enrollment on our U.S. phase II study during the Q1 calendar year of 2021

• Cleared PEI (Germany’s health regulatory agency, the Paul Ehrlich Institute) commencement of PhaseII Study in Germany in August 2020

20

COVID-19 Clinical Programs

* Compared to 3.3% (38 out of 1151 patients) in data published inthe NY area during March-April 2020 for patients requiringmechanical ventilation and discharged alive (Richardson S et al.Presenting Characteristics, Comorbidities, and Outcomes Among5700 Patients Hospitalized With COVID-19 in the New York CityArea. JAMA 2020. doi:10.1001/jama.2020.6775)

Design Phase II, randomized, Double-Blind, Placebo-controlled

Study population Hospitalized, mechanically ventilated, adult patients suffering from respiratory failure and ARDS due to COVID-19

Countries U.S. , Germany

Sample size 140 patients

Study design 600M cells – 1 administration300M cells – 2 administrations 300M cells 1 administration + Placebo 1 administrationPlacebo – 1 administrationPlacebo – 2 administrations

Administration IM injections

Primary efficacy endpoint Number of ventilator free days during the 28 days from day 1 through day 28 of the study

Secondary efficacy endpoints All cause mortality; Duration of mechanical ventilation, mean improvement relative to baseline on a 7-point ordinal scale, ICU-free-days, hospitalization-free days

Follow Up length Safety and survival follow-up will be conducted at day 60, week 26 and week 52

Expected end of enrollment U.S. phase II study - during the Q1 calendar year of 2021 21

PLX-PAD as a Treatment for ARDS Due to COVID-19

PLX-R18

Hematological Deficiencies

22

• Acute Radiation Syndrome (ARS) Studies conducted and funded by U.S. government (NIH, DOD) FDA has cleared Pluristem’s Investigational New Drug (IND) application for PLX-R18 in the treatment

of ARS in case of nuclear events FDA Orphan Drug Designation

• Phase I – Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation (HCT) N= 20 Open-label trial, allows for interim data analysis Clinical sites in U.S & Israel FDA Orphan Drug Designation Data from first two cohorts showed PLX-R18 led to increased production of

platelets & red blood cells, ultimately reducing the number of required transfusions Expected top-line results - during the Q1 calendar year of 2021

Hematological Programs

23

PLX-R18 is designed to stimulate the regeneration of damaged bone marrow to produce blood cells (white, red and platelets)

PLX-R18 as a Treatment for ARS (via the FDA Animal Rule)

24

Series of studies conducted by the U.S. National Institutes of Health (NIH), testing PLX-R18 as apotential treatment for ARS

• EIB signed a €50 million non-dilutive financing agreement with Pluristem

• Purpose:

To support Pluristem’s research and development in the EU to further advance its regenerative celltherapy platform, and to assist moving the products in its pipeline to market

A special focus on clinical development of PLX cells as a treatment for complications associated withCOVID-19

EIB will support up to 50% of the cost of the project

• Will be available for a period of 3 years, in three tranches, subject to the achievement of certain clinical,regulatory and scaling up milestones: first tranche consisting of €20 million, second of €18 million and thethird €12 million

• Will be payable to the EIB in a single payment following five years from the disbursement of the first andsecond tranches and in two annual payments starting on the fourth year from disbursement of the thirdtranche, with each tranche having an interest rate of between 3%-4%

• EIB would be entitled to receive royalties from future revenues for a period of seven years starting 2024,at a rate of 0.2% to 2.3%, pro-rated to the amounts that the Company received

25

The European Investment Bank (EIB) –€50 Million Non-Dilutive Financing

26

Regulatory support

Governmental agencies collaborators and

projects

Significant Regulatory and Government Support

27

Pluristem keeps IP and manufacturing rights in all collaborations

Partnerships and Collaborations

28

Chen Franco-YehudaCFO

Liran Shani, MDVP Clinical & Medical Affairs

Efrat Livne-HadassVP Human Resources

Lior RavivVP Operations & Development

Efrat KaduriDirector of Marketing & Business Development

Orly AmiranVP Quality Assurance

Racheli Ofir, Ph.D. VP Research & Intellectual Property

Yaky YanayCEO & President

Zami AbermanExecutive Chairman

Management Team

Investor.relations@Pluristem.com www.Pluristem.com

29

Israel +972-74-710-8600

U.S. +1-347-973-2098

Germany +49-30-2215-0786